According to a recent study, a critically ill patient infected with the new coronavirus has made an astounding recovery after receiving umbilical cord stem cell therapy.

Are there other studies using stem cells to treat COVID-19?

Many researchers have said that stem cell therapy is an inevitable trend for treating virus-induced pneumonias such as the new coronavirus. Various other clinical trials have recently emerged, which are also investigating umbilical cord stem cells in COVID-19 treatments. Amongst these is a collaborative project that is being led by researchers from Shanghai University and Peking Union Medical College (PUMC), Chinese Academy of Medical Sciences.

7 patients with COVID-19 were involved with this study and were administered mesenchymal stem cells via injection. Symptoms of all patients were significantly alleviated within just two days of the treatment, showing no adverse effects. Three of these patients were discharged 10 days after the stem cell treatment. The researchers of this project have described these results as “encouraging and exciting”.

Since it was launched, the study has continued to treat over 30 patients infected with COVID-19. All of these patients have shown significant improvements in their condition following stem cell therapy.

Additionally, another four COVID-19 patients who received stem cell treatments while in a critical condition have been discharged from hospital after making a full recovery. Another research team from the Chinese PLA General Hospital is working with hospitals and institutions in Wuhan to conduct clinical research on the safety and effectiveness of mesenchymal stem cell therapy in treating COVID-19 patients. Clinical trials such these continue to provide hope among healthcare and medical professionals alike.

What is COVID-19?

COVID-19 is a highly infectious disease that has never been encountered before. The coronavirus was first reported in Wuhan, Hubei Province, China, December 2019, followed by an outbreak across China and other parts of the world.

The type of pneumonia caused by the COVID-19 so infectious that the ongoing outbreak has been declared by the World Health Organisation as a pandemic.

Mesenchymal stem cells (MSCs) which are found in umbilical cord blood, are known for their anti-inflammation and immune regulation functions, which can significantly improve the immune environment in the lungs and reduce the risk of respiratory failure.

The use of MSCs in these clinical trials have improved even the patients showing severe symptoms of COVID-19 and pneumonia by regulating inflammatory responses and promoting tissue repair and regeneration, helping them to recover.